Search the Newsreel

NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal

NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and …

EEFT Q2 Deep Dive: Digital Accelerators Offset Cross-Border and Travel Headwinds

EEFT Q2 Deep Dive: Digital Accelerators Offset Cross-Border and Travel Headwinds Financial technology provider Euronet Worldwide (NASDAQ:EEFT) fell short of the market's revenue expectations in Q2 CY2026 as sales rose 3.2% year on year to $1.11 billion. Its non-GAAP profit of $2.82 per share …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Price to book forward of Neuropace, Inc. – NASDAQ:NPCE

This page provides financial information for Neuropace, Inc. (NASDAQ: NPCE), specifically focusing on its price to book forward ratio. It includes links to various financial data, news, and community sections related to the company on the TradingView platform.

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Aspen's Parkinson's Cell Therapy Gets FDA RMAT Designation—Not Approval

ClearPoint Neuro announced that its partner Aspen Neuroscience received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, an investigational Parkinson's disease therapy. This designation expedites development and review but does not constitute FDA approval. ClearPoint Neuro's Navigation System and SmartFlow Cannula are utilized …

Trading the Move, Not the Narrative: (NPCE) Edition

This article provides an AI-driven analysis of Neuropace Inc. (NPCE), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis emphasizes elevated downside risk …

Did Weaker Q2 Profit and Heavy Buybacks Just Shift Euronet Worldwide's (EEFT) Investment Narrative?

Euronet Worldwide reported past second-quarter 2026 results with sales of US$1,108.4 million, net income of US$77.4 million, and diluted EPS from continuing operations of US$1.71, compared with the prior year's higher profitability. Alongside these results, the company completed a major share repurchase program launched …

Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE

Neuropace, Inc. (NASDAQ: NPCE) generated $99.99 million in revenue last year, primarily from its Medical Device segment, which contributed the entire amount. This marks an increase from $79.91 million in the previous year. The United States was the company's largest market, accounting for all …

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro congratulates its partner Aspen Neuroscience on receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001), an investigational autologous cell replacement therapy for Parkinson's disease. This designation will support an expedited development and review pathway for Aspen's therapy, which utilizes …

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …

North European Oil Royalty Trust declares $0.26 per unit fiscal Q3 2026 distribution

North European Oil Royalty Trust has declared a distribution of $0.26 per unit for its fiscal third quarter of 2026, payable on August 31 to unitholders of record on August 17. This distribution matches the year-ago quarter's amount and represents an increase from $0.22 …

Eurodry Ltd. Revenue Breakdown – FWB:0LQ

Eurodry Ltd. generated 44.50 million EUR in revenue last year. The Time Charter segment was the top-performing segment, contributing 47.37 million EUR, although this was a decrease from 62.58 million EUR in the previous year. The company's revenue primarily came from the Global region.

EUROBANK S.A. Revenue Breakdown – DUS:1X8

Euronext NV (EUXTF) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Fueled by ...

This article first appeared on GuruFocus. Revenue: Record underlying revenue and income of EUR544.4 million, up 16.9% year-on-year. Adjusted EBITDA: Reached a record EUR360 million, up 21.1% year-on-year. Adjusted EBITDA Margin: 66.1%, an improvement of 2.3 percentage points compared to Q2 2025. Adjusted Net …

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside

Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 …

Vanguard Capital Management (EEFT) discloses 4.9% beneficial stake in Euronet Worldwide

Vanguard Capital Management LLC has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Euronet Worldwide Inc. This represents 1,866,508 shares, with Vanguard holding sole voting power over 279,813 shares and sole dispositive power over all 1,866,508 shares. The filing aggregates …

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

Neurocrine Biosciences, Inc. NBIX highlighted the continued expansion of its commercial portfolio during its second-quarter 2026 earnings call, with management emphasizing growth from INGREZZA, CRENESSITY and the newly acquired VYKAT XR. The company also outlined upcoming clinical catalysts and its strategy to diversify beyond …

Euronet Q2 Earnings Miss Estimates on Cross-Border Payments Weakness

Euronet Worldwide, Inc. (EEFT) reported second-quarter 2026 adjusted earnings per share and total revenues that missed Zacks Consensus Estimates, despite a year-over-year increase in both metrics. The miss was primarily attributed to higher operating expenses and weakness in its Cross-Border Payments segment. However, strong …

EuroDry to discuss second-quarter results on Aug. 6 webcast

EuroDry Ltd. (NASDAQ: EDRY) will release its second-quarter 2026 financial results on August 6, 2026, before the New York market opens. Management will host a conference call and webcast at 9:30 a.m. Eastern Time on the same day to discuss the results. The company's …

EuroDry updates financial calendar with second-quarter results release, conference call and webcast

EuroDry has announced its financial calendar update, revealing that its Q2 2026 financial results will be released on August 6, 2026, before the New York market opens. Management will host a conference call and webcast on the same day at 9:30 a.m. ET to …

Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat

Guggenheim has increased its price target for Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares to $222 from $200, maintaining a Buy rating after the company's strong second-quarter results. The company reported Ingrezza sales significantly above consensus and raised its full-year 2026 Ingrezza sales guidance, driven by …

North European Oil Royality Trust (NYSE:NRT) Raises Dividend to $0.26 Per Share

North European Oil Royalty Trust (NYSE:NRT) has announced an 18.2% increase in its quarterly dividend to $0.26 per share, up from $0.22. This dividend, which implies an annualized yield of approximately 11.7%, is payable on August 31 to shareholders of record by August 17. …

EuroDry (EDRY) Upgraded to Buy: Here's What You Should Know

EuroDry (EDRY) has been upgraded to a Zacks Rank #2 (Buy), driven by an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in earnings estimates and near-term stock price movements, suggesting a positive outlook for EDRY. Analysts …

Euronet Worldwide Number of Employees 2026 | Employee Count & Headcount Data

Euronet Worldwide (EEFT) has approximately 10,873 employees worldwide as of March 2026, representing a 7.1% growth since 2023 but a 1.4% decline year-over-year in 2026. The company, headquartered in Leawood, Kansas, is actively hiring with 618 job postings and has a global average salary …

EuroDry Ltd. Sets Date for the Release of Second Quarter 2026 Results, Conference Call and Webcast

EuroDry Ltd. (NASDAQ: EDRY) announced it will release its second quarter 2026 financial results on August 6, 2026, before market open. The company will also host a conference call and webcast on the same day at 9:30 a.m. Eastern Time to discuss the results. …

[10-Q] NEUROCRINE BIOSCIENCES INC Quarterly Earnings Report

Neurocrine Biosciences Inc. (NBIX) filed its quarterly earnings report (Form 10-Q) with the SEC, detailing its financial performance for the quarter ended June 30, 2026. Key highlights include the completion of the Soleno Therapeutics Inc. acquisition, adding VYKAT XR to its commercial portfolio, and …

EDRY|EuroDry Ltd|Price:25.740|Chg%:+1.450

This article provides a comprehensive financial overview of EuroDry Ltd (EDRY), detailing its income statement, balance sheet, and cash flow statement. It includes quarterly and annual financial indicators such as EPS, revenue, net profit, and various margin ratios, alongside key financial figures from the …

Neuropace Inc (NPCE) Institutional Confidence

Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, ranking 1st out of 199 in its industry. The institutional shareholding proportion is 99.26%, showing a 7.21% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.51% of outstanding shares.

Dimensional Fund Advisors LP Boosts Position in Euronet Worldwide, Inc. $EEFT

Dimensional Fund Advisors LP has increased its stake in Euronet Worldwide, Inc. (NASDAQ:EEFT) by 22.8% in the first quarter, now owning 1,213,928 shares valued at over $80 million. Other institutional investors like Geneos Wealth Management Inc. and Evergreen Capital Management LLC also adjusted their …

North European Oil Royality Trust (NYSE:NRT) Short Interest Up 68.1% in July

North European Oil Royalty Trust (NYSE:NRT) experienced a significant

Euroseas Ltd (ESEA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Euroseas Ltd (ESEA), detailing its current risk score, beta value, and various volatility and financial risk metrics. The company's risk assessment score is 5.40, ranking 37th in the Freight & Logistics Services industry, with a beta of …

AIFF Q3 1998 Earnings: Pre-Revenue Neurotech Firm Posts Deep Loss While Shares Advance - Earnings Weakness Phase

North European Oil Royalty Trust (NRT) Surges 7.2% to $9.51 on Renewed Energy Sector Interest - Stop Hunt